Kim Fox ivabradine guidelines case exposes £50m COI in ESC task force
A BMJ investigation details how Kim Fox's £50m Servier-linked contracts overlapped with his leadership of ESC ivabradine guidelines, later ruled severe misconduct by the society. The case highlights systemic weaknesses in voluntary disclosure and raises doubts about guideline integrity. Reforms toward statutory transparency are now under discussion in Europe.
Former ESC vice president John Martin demands a full public inquiry, arguing the board risks appearing complicit without external review. Reforms proposed include mandatory divestment from sponsor contracts during guideline service and retrospective audits of past panels. The episode coincides with broader European moves to replace self-regulation with legal transparency requirements modeled on US Sunshine Act provisions. Without such changes, similar conflicts in heart failure and arrhythmia guidelines remain probable given the concentration of industry funding in device and drug trials.
ESC: Within 18 months, at least two national cardiology societies will mandate public divestment audits for guideline chairs, triggered if similar payment disclosures exceed £5m.
Sources (3)
- [1]A monstrous conflict of interest: Kim Fox, ivabradine, and European Society of Cardiology clinical practice guidelines(https://www.bmj.com/content/392/bmj-2026-100440)
- [2]Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61198-1/fulltext)
- [3]Heart rate as a target in ischaemic heart disease (BEAUTIFUL)(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61540-4/fulltext)